等待開盤 03-26 09:30:00 美东时间
+0.330
+11.30%
Swarmer上市首日暴涨520%,公司称其无人机技术经历过实战验证;ALOY大涨22%,研制出更清洁、成本更低稀土提取新技术;CTRN升17%,财报强劲指引超预期>>
03-18 18:58
Aemetis shares are trading higher after the company reported better-than-expect...
03-13 01:58
Aemetis (NASDAQ:AMTX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.21) by 62.79 percent. This is a 74.19 percent increase over losses of $(0.31) per share from the same
03-12 20:01
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Aemetis, Inc. (NASDAQ:AMTX), a renewable natural gas and renewable liquid fuels company focused on lower cost and reduced emissions products, today announced that its Aemetis Biogas LLC subsidiary received funds from the
2025-12-30 21:05
Aemetis Biogas LLC, a subsidiary of Aemetis, Inc., received $17 million from the sale of federal clean energy tax credits, including $12 million from a Section 48 ITC for constructing a dairy manure digester and $5 million from a Section 45Z PTC for renewable natural gas production in 2025. Net proceeds were $15 million after costs. Eric McAfee, Aemetis' Chairman and CEO, highlighted this as a significant step toward monetizing tax incentives and...
2025-12-30 13:00
Aemetis has received permits for its mechanical vapor recompression (MVR) project at its Keyes ethanol plant, which is expected to boost annual cash flow by $32 million starting mid-2026. The project, funded by $19.7 million in grants, aims to reduce natural gas usage by 80%, lower carbon intensity, and increase tax credits. Completion is slated for Q2 2026, furthering Aemetis' decarbonization efforts and renewable fuel production in California.
2025-12-02 13:00
今日重点评级关注:富国银行:维持Annexon"超配"评级,目标价从14美元升至27美元;瑞穗:上调Relmada Therapeutics评级至"跑赢大市",目标价从1美元升至10美元
2025-11-20 10:28
Ascendiant Capital analyst Edward Woo maintains Aemetis (NASDAQ:AMTX) with a Buy and lowers the price target from $21 to $20.
2025-11-19 18:28
Aemetis (NASDAQ:AMTX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.20) by 85 percent. This is a 2.63 percent increase over losses of $(0.38) per share from the same
2025-11-06 20:58